Pneumonia Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028
Global Pneumonia Market: Overview
Pneumonia vaccines are recommended for adults and children for a wide range of clinical conditions. The bacteria Streptococcus pneumoniae is responsible for pneumococcal infections causing otitis media, bacteremia, pneumonia, and meningitis. Unconjugated as well as conjugated pneumococcal polysaccharide vaccines have been used with success for reducing the rate of pneumococcal infections, especially in adults and children.
Considerable research has been made in expanding understanding of pneumococcal immunobiology. In the light of rapidly aging populations in low and middle-income countries, vaccine manufacturers have focused on vaccine efficacy, apart from cost effectiveness. Demand for prevention of invasive pneumococcal disease has helped shape the approaches for manufacturers. At-risk populations include individuals with diabetes, asthma, chronic obstructive pulmonary disease, human immunodeficiency virus (HIV), sickle cell disease, and cardiovascular diseases.
The report on the global pneumonia vaccines market takes a closer look at winning imperatives by top players, technological advances, and the risk factors related to specific factors.
Global Pneumonia Vaccines Market: Key Developments
In recent years, vaccine manufacturers in the pneumonia vaccines market have started focusing on immunocompromised populations and children. Particularly, their initiatives have facilitated the development of potential vaccine antigens. To this end, they are including most common serotypes for preventing invasive pneumococcal diseases in paediatrics.
Pfizer Inc., a U.S.-based multinational pharmaceutical corporation, recently revealed (September 2019) that it has made headways in phase II study on its 20-valent pneumococcal conjugate vaccine. The proof-of-concept study is aimed at evaluating its candidate, PF-06482077 and the data recently threw open encouraging results. The company is developing its pneumococcal vaccine for treating invasive diseases and otitis media in healthy infant populations. The candidate, the company found similar safety profile, as its Prevnar 13, a 13-valent pneumococcal conjugate vaccine. Of note, it contains 20 serotypes and the data showed a positive immune response.
The pharmaceutical company hopes to test the efficacy of the candidate for adult populations. To this end, it announced that it enrolled three phase III clinical trials. This is a lucrative business for numerous other top pharmaceutical companies. A case in point is Merck developing 15-valent pneumococcal conjugate vaccine candidate, V114.
Global Pneumonia Vaccines Market: Growth Dynamics
Over the past few years, several pharmaceutical and biopharmaceuticals have enrolled themselves in evaluating candidates of developing pneumococcal conjugate vaccines. This type of vaccine has been occupying sizable shares in the market. Their efforts are invigorating the drug pipeline in the pneumonia vaccines market. Mounting concern of the risk of community-acquired pneumonia is also boosting new developments in various developing and developed countries. The awareness about preventive care in community-acquired pneumonia has reinforced the need for timely vaccination against pneumococcus.
Patients with chronic pulmonary conditions show considerable risk factor. The high risk of mortality of invasive pneumococcal diseases has spurred research pertaining to this patient cohort, thereby unlocking new prospects in the pneumonia vaccines market. In recent decades, shifting serotype dominance has led pharmaceuticals to doubt the efficacy of polysaccharide vaccine. This aside, increasing trend of antibiotic resistance has spurred research in pneumococcal vaccines that can cover against wide range of pneumococci antigens. This has opened new avenues in the pneumonia vaccines market.
Growing focus of NGOs and global agencies on pneumonia prevention strategies has augmented the role of vaccines. These organizations have been relentlessly working on the affordability of pneumococci vaccines in low- and middle-income countries.
Global Pneumonia Vaccines Market: Regional Analysis
Some of the key regional markets for pneumonia vaccines are North America, Europe, Asia Pacific, and LAMEA. Of these, North America has made considerable progress in vaccine developments. Particularly, progress made in development of vaccines for the development of invasive pneumococcal diseases has also reinforced lucrative avenues to vaccine manufacturers. Meanwhile, Asia Pacific is witnessing new advances in vaccine strategy. This has opened new revenue streams in the global pneumonia vaccines market.
This study provides a particularized anatomy according to the L.E.A.P mechanism
The regional analysis offers market assays across:
The study, prepared through the L.E.A.P mechanism adds a dimension of infallibility and assures precise information on all the growth dynamics.
Latest Trends and Cardinal Growth Prospects
The study assists in burnishing the knowledge of the stakeholder in terms of the emerging trends. The study provides an expansive coverage on the latest developments and novel profit-yielding sources that augur well with the market. A dedicated and determined team of experts conduct an out-and-out research on diverse aspects to offer ultimate breakthroughs in the market.
Existing and Future Insights in Growth
The interfusion of ubiquitous primary and secondary research through modern tools invites perfection and accuracy in every aspect. Primary research is circumspectly conducted through exhaustive interactions and interviews of experts. These valuable opinions are then neatly inducted in the report to allow the stakeholder for reaping the benefits. A treasure of secondary data is extracted via famed paid sources, yearly estimates and statements, renowned journals, and government documents. These sources assist in creating a robust database comprising existing and subsequent growth dynamics.
Ascensions in Technology
Diverse technological advancements and cutting-edge innovations in the market have been covered in this study to assist the stakeholder in research and development activities. Recent upgrades have also been added in the study, thus helping the stakeholder to paint the strokes of growth on the canvas of the market.
The study presents a plethora of challenges and obstacles that can hinder the growth of the market to allow the stakeholder to prepare their strategies accordingly.
The world ushered in the new decade with the shadow of the COVID-19 pandemic. The outbreak has damaged the growth prospects of several businesses and has crippled the entire economy. The study is in tandem with the changing dynamics of the market due to the SARS-CoV-2 outbreak. The study focuses on the coronavirus pandemic and analyses every aspect that impacts the growth positively or negatively.
An aerial perspective of the regions covered in this study enables the stakeholder to design strategies accordingly. The 360-degree assessment of every aspect associated with growth offers information on a rainbow of growth opportunities available across the market.
The exhaustive study motivates the stakeholder to take the 'LEAP' of faith and achieve success!
This report is the key to questions such as:
What are the prominent factors that will help in reshaping the market growth?
Which trends have the potential to bring expansive growth for the market?
What are the necessary strategies to overcome the ill-effects of the COVID-19 pandemic?
Which regions will emerge as champion growth contributors for the market?
Which aspects will serve as game-changers for the market?
What are the latest innovations in the market?
Which factors will hinder the growth of the market?
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report